Intellia Therapeutics, Inc.(NTLA)

Description: Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Medicine Biotechnology Emerging Technologies Biology Immune System Molecular Biology Genetics Hepatitis B Liver Disease Metabolism Precision Medicine Chimeric Antigen Receptor T Cell Amyloidosis Hematopoietic Stem Cell Amyloid Antitrypsin Deficiency CRISPR Hepatitis B Virus Chimeric Antigen Receptor Genome Editing Transthyretin Cell Product Inborn Errors Of Metabolism Cas9 Transthyretin Amyloidosis Biological Tool Intellia Therapeutics

---

Home Page: www.intelliatx.com

NTLA Technical Analysis

40 Erie Street
Cambridge, MA 02139
United States
Phone: 857 285 6200

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)